Journal: Stem cell research & therapy

Article Title: VEGF-B-mediated myofiber types involved in high-fat diet-induced hyperglycemia through PKA-NFATs signaling pathway.

doi: 10.1186/s13287-025-04455-7

Figure Lengend Snippet: Fig. 8 Schematic diagram of this work. (A) VEGF-B acts as a bridge between skeletal muscle type and high-fat diet-induced hyperglycemia in vivo. (B) Matched with high-fat diet-induced hyperglycemia accompanied by increased content of slow-twitch type I fibers within the skeletal muscle of VEGF-B deficient high-fat diet-fed mice in vivo, VEGF-B186, which was continuously administered at a single high dosage in vitro, inhibited myoblast differentia tion/fusion and myofiber formation and glucose utilization via the PKA-NFATs signaling pathway

Article Snippet: The primary antibodies used were as follows: MyHC (1:3000, sc-376157, Santa Cruz, Dallas, Texas, USA), α-tubulin (1:10000, YM3035, Immunoway®, Newark, USA), PKA α/β/γ cat (1:1000, sc-365615, Santa Cruz, Dallas, Texas, USA), PKA α cat (1:3000, sc-28315, Santa Cruz, Dallas, Texas, USA), PKA γ cat (1:1000, sc-514087, Santa Cruz, Dallas, Texas, USA), PKA Iα reg (1:1000, sc-136231, Santa Cruz, Dallas, Texas, USA), PKA IIα reg (1:3000, sc-136262, Santa Cruz, Dallas, Texas, USA), PKA Iβ reg (1:2000, sc-100414, Santa Cruz, Dallas, Texas, USA), GLUT4 (1:2000, YT5523, Immunoway®, Newark, USA), NOQ (1:1000, ab11083, Abcam Corporation, Cambridge, England), My32 (1:1000, ab51263, Abcam Corporation, Cambridge, England), Nfatc1 (1:1000, ab25916, Abcam Corporation, Cambridge, England), Nfatc2 (1:1000, 5861T, Cell Signaling Technology Inc., Danvers, Massachusetts, USA), P-Nfatc1 (1:1000, ab183023, Abcam Corporation, Cambridge, England), P-Nfatc2 (1:1000, ab200819, Abcam Corporation, Cambridge, England), and Lamin B1 (1:5000, P60054, Abmart Shanghai Co., Ltd., Shanghai, China).

Techniques: In Vivo, In Vitro